ABA + MTX | ABA + HCQ | ABA + SSZ | ABA + AZA | ABA + LEF | |
---|---|---|---|---|---|
ATTAIN cohort | (n = 175) | (n = 11) | (n = 10) | (n = 4) | (n = 17) |
Female, n (%) | 140 (80) | 8 (73) | 7 (70) | 3 (75) | 14 (82) |
Age (years) | 52.85 (11.79) | 52.91 (15.02) | 55.10 (14.29) | 63.50 (16.43) | 50.76 (15.03) |
DAS28 (ESR) | 6.9 (1.03) | 7.0 (0.73) | 6.6 (0.75) | 7.3 (1.19) | 7.2 (1.08) |
CDAI LDA/remission, n (%) | – | – | – | – | – |
RF positive, n (%) | 129 (74) | 9 (82) | 7 (70) | 1 (25) | 12 (71) |
ACPA positive, n (%) | – | – | – | – | – |
ASSURE cohort | (n = 535) | (n = 35) | (n = 36) | (n = 10) | (n = 62) |
Female, n (%) | 439 (82) | 33 (94) | 28 (78) | 10 (100) | 47 (76) |
Age (years) | 52.19 (12.11) | 54.77 (11.13) | 53.89 (12.47) | 51.10 (6.90) | 54.76 (10.42) |
DAS28 (ESR) | – | – | – | – | – |
CDAI LDA/remission, n (%) | – | – | – | – | – |
RF positive, n (%) | – | – | – | – | – |
ACPA positive, n (%) | – | – | – | – | – |
ARRIVE cohort | (n = 490) | (n = 49) | (n = 32) | (n = 30) | (n = 65) |
Female, n (%) | 405 (83) | 43 (88) | 22 (69) | 25 (83) | 53 (82) |
Age (years) | 55.35 (12.32) | 51.31 (11.54) | 57.00 (13.69) | 55.27 (11.30) | 53.38 (11.4) |
DAS28 (CRP) | 6.2 (0.72) | 6.3 (0.81) | 6.2 (0.75) | 6.1 (0.74) | 6.1 (0.72) |
CDAI LDA/remission, n (%) | – | – | – | – | – |
RF positive, n (%) | 296 (60) | 31 (63) | 20 (63) | 23 (77) | 34 (52) |
ACPA positive, n (%) | – | – | – | – | – |
ACTION cohort | (n = 1182) | (n = 57) | (n = 45) | (n = 15) | (n = 253) |
Female, n (%) | 926 (78) | 45 (79) | 35 (78) | 9 (60) | 204 (81) |
Age (years) | 57.48 (12.31) | 58.16 (13.16) | 57.76 (11.89) | 58.80 (14.11) | 56.10 (13.59) |
DAS28 (ESR) | 5.4 (1.25) | 5.5 (1.19) | 5.5 (1.32) | 5.4 (1.44) | 5.4 (1.37) |
CDAI LDA/remission, n (%) | 31 (3.1) | 1 (2.2) | 2 (4.7) | 1 (8.3) | 14 (6.6) |
RF positive, n/N (%) | 738/1027 (71.9) | 33/49 (67.3) | 27/37 (73.0) | 7/11 (63.6) | 142/205 (69.3) |
ACPA positive, n/N (%) | 667/981 (68.0) | 28/40 (70.0) | 27/38 (71.1) | 7/10 (70.0) | 116/183 (63.4) |